What's in Seattle Urology Research Center's pipeline?

Seattle Urology Research Center has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Seattle Urology Research Center's portfolio?

Top competitors by shared drug class: Astellas Pharma Inc, Barrie Urology Associates, National Taiwan University Hospital, Pfizer, Weill Medical College of Cornell University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/seattle-urology-research-center.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Seattle Urology Research Center — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Seattle Urology Research Center pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Solifenacin PO	Solifenacin PO	marketed	Muscarinic M3 receptor antagonist	M3 muscarinic acetylcholine receptor	Urology

Therapeutic area mix

Urology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Astellas Pharma Inc · 1 shared drug class
Barrie Urology Associates · 1 shared drug class
National Taiwan University Hospital · 1 shared drug class
Pfizer · 1 shared drug class
Weill Medical College of Cornell University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Seattle Urology Research Center:

Cite this brief

Drug Landscape (2026). Seattle Urology Research Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/seattle-urology-research-center. Accessed 2026-05-18.